Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 18/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485009 | 0.86 | GRIN2B (0.53) | GRIN2B | |
| SCHEMBL3485004 | 0.86 | GRIN2B (0.53) | GRIN2BGRIN1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL3484822 | 0.85 | GRIN2B (0.52) | GRIN2BGRIN1PARP1 | |
| SCHEMBL3045422 | 0.83 | EGLN1 (0.53) | GRIN2BGRIN1 | |
| SCHEMBL31731759 | 0.83 | EGLN1 (0.53) | GRIN2BGRIN1 | |
| SCHEMBL3484710 | 0.83 | EGLN1 (0.57) | GRIN2BGRIN1 | |
| SCHEMBL3485355 | 0.80 | GRIN2B (0.48) | GRIN2BGRIN1PARP1 | |
| SCHEMBL3485270 | 0.80 | GRIN2B (0.47) | GRIN2BGRIN1PARP1ALDH1A1 | |
| SCHEMBL14331171 | 0.79 | GRIN2B (0.51) | GRIN2B | |
| SCHEMBL3485426 | 0.76 | PARP1 (0.50) | GRIN2BGRIN1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GRIN2B 4440/4885GRIN1 4305/4885PARP1 184/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GRIN2B 4440/4885GRIN1 4305/4885PARP1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.